Our collaborators Dundee who oversee the EMBARC network have two bronchiectasis trials which will start very soon and are looking for new sites to join the studies. A brief description of the VITAL-BE and GREAT-2 studies can be viewed below. If either of these trials are of interest to your research team, please do not hesitate to get in touch using the contact details below.
Expressions of interested wanted for new sites for the VITAL-BE trial
Are you interested in contributing to investigator led research into treatment for people with bronchiectasis?
The VITAL-BE trial is a double blind, randomized, placebo controlled trial of inhaled aztreonam vs placebo in patients with bronchiectasis. The key inclusion criteria are the presence of Gram-negative bacteria in sputum (including Pseudomonas aeruginosa, but patients with other Gram negative organisms can also be enrolled) and a history of 3 exacerbations per year. Patients receive treatment for 12 months to determine the impact of inhaled antibiotic treatment on exacerbations and symptoms.
We are seeking new sites to participate in the trial and seek expressions of interest from interested sites. Sites would be asked to recruit 3-5 patients.
This study is investigator led and delivered by Tayside Clinical Trials Unit, Dundee.
Thank you for considering supporting this trial.
Expressions of interested wanted for new sites for the GREAT-2 trial
Bronchiectasis patients with Pseudomonas aeruginosa infection often have frequent exacerbations and poor quality of life and so new treatments are urgently required.
The GREAT-2 trial is a double blind randomized placebo controlled trial of a novel antibody therapy directed against Pseudomonas aeruginosa being conducted in the UK and other countries. The trial is led by EMBARC, the European Bronchiectasis Network and is supported by the European Respiratory Society.
We aim to recruit patients with bronchiectasis and chronic P. aeruginosa infection. Patients are eligible to participate even if they receive other antibiotic treatments to control their condition. Patients will participate in the trial for a total of 6 months.
We seek investigators interest to participate. The trial is led by Tayside Clinical Trials Unit (TCTU). You can get more information about the study by contacting Margaret Band at firstname.lastname@example.org
If you think you may be interested to participate please contact us and support bronchiectasis research.